Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05768165
Other study ID # Vastra Gotaland record 275642
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 16, 2021
Est. completion date March 30, 2024

Study information

Verified date March 2024
Source Vastra Gotaland Region
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiovascular performance and overall fitness can be improved by high-intensity aerobic activity, and these benefits may be achievable by persons with rheumatic diseases. The investigators hypothesize that a 12-week high-intensity interval exercise program will provide substantial improvements in cardiovascular function, inflammation and symptoms affecting quality of life.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 87
Est. completion date March 30, 2024
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: - Rheumatoid arthritis disease according to the American College of Rheumatology (ACR)/ The European Alliance of Associations for Rheumatology (EULAR) 1987/2010 criteria - Disease duration >1 year - Age (range 20-60 years) - Stable medication on anti- rheumatic drugs for >3 months - Low-to-moderate disease activity (<5.1) according to the Disease activity score 28 (DAS28) Exclusion Criteria: - Cerebrovascular diseases - Diabetes - Severe hypertension - Chronic obstructive pulmonary disease or other severe pulmonary diseases - Other severe diseases that may be associated with adverse events or restrict participation in high-intensity exercise - Arthroplasty of large joints - Inability to manage Cardiopulmonary Exercise Testing (CPET) - Pregnancy - Already participating in regular aerobic or strength exercise at a high intensity level (>1 hours/ week) during the last 6 months - Inability to speak or read Swedish.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High intensity exercise
Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets. Exercise guidance follows principles of self-efficacy and person-centeredness.

Locations

Country Name City State
Sweden Sahlgrenska university hospital Göteborg
Sweden Uddevalla Hospital Uddevalla

Sponsors (2)

Lead Sponsor Collaborator
Vastra Gotaland Region Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiopulmonary function Maximum oxygen uptake (VO2ml/min/kg) (Higher value indicate better cardiorespiratory capacity) 0 -12 weeks
Secondary Vascular function Aortic pulse wave velocity (PWV) (m/sec.) (Higher PWV value indicate worse vascular function) 0-12 weeks
Secondary Level of disease activity Disease activity score 28 (DAS28) (Range 0-10 where a higher score indicate worse disease activity) 0-12 weeks
Secondary Level of disease activity Disease activity score 28 (DAS28) (Range 0-10 where a higher score indicate worse disease activity) 0-6 months
Secondary Level of disease activity Disease activity score 28 (DAS28) (Range 0-10 where a higher score indicate worse disease activity) 0-12 months
Secondary Homeostatic model assessment of insulin resistance (HOMA IR) Measure of insulin resistance (fasting glucose (mmol/L) and fasting insulin (mIU/ L) will be combined to report HOMA IR 0-12 weeks
Secondary Glycosylation level of hemoglobin (HbA1c) Glycosylation level of hemoglobin (mmol/mol) 0-12 weeks
Secondary Level of blood lipids Levels of triglycerides (mmol/L), Level of high-density lipoprotein (HDL) (mmol/L), low-density lipoprotein (LDL) ( mmol/L), Total cholesterol (mmol/L ) 0-12 weeks
Secondary Erythrocyte Sedimentation Rate (ESR) Level of high sensitivity ESR (mm/h) (Higher score indicate higher inflammation) 0-12 weeks
Secondary Erythrocyte Sedimentation Rate (ESR) Level of high sensitivity ESR (mm/h) (Higher score indicate higher inflammation) 0-6 months
Secondary Erythrocyte Sedimentation Rate (ESR) Level of high sensitivity ESR (mm/h) (Higher score indicate higher inflammation) 0-12 months
Secondary C-Reactive Protein (CRP) Level of high sensitivity CRP (mg/L) (Higher score indicate higher inflammation) 0-12 weeks
Secondary C-Reactive Protein (CRP) Level of high sensitivity CRP (mg/L) (Higher score indicate higher inflammation) 0-6 months
Secondary C-Reactive Protein (CRP) Level of high sensitivity CRP (mg/L) (Higher score indicate higher inflammation) 0-12 months
Secondary Cytokine levels Interleukin-6 (pg/mL), interleukin-10 (pg/mL), tumour necrosis factor-alpha (pg/mL) 0-12 weeks
Secondary Muscle function of lower extremities The one minute sit-to-stand test (Higher numbers of complete rises indicate better muscle function in lower extremities) 0-12 weeks
Secondary Hand-grip force Hand-grip force is assessed with a dynamometer ( Higher value indicate better grip strength) 0-12 weeks
Secondary Self-reported physical activity Self-reported questionnaire of habitual physical activity during a typical week. Numbers of hours on low, moderate and high intensity is summed for each category (A minimum of 150 minutes on moderate intensity or 75 minutes on high intensity are equal to health enhancing physical activity according to World Health Organization guidelines) 0-12 weeks
Secondary Self-reported physical activity Self-reported questionnaire of habitual physical activity during a typical week. Numbers of hours on low, moderate and high intensity is summed for each category (A minimum of 150 minutes on moderate intensity or 75 minutes on high intensity are equal to health enhancing physical activity according to World Health Organization guidelines) 0-6 months
Secondary Self-reported physical activity Self-reported questionnaire of habitual physical activity during a typical week. Numbers of hours on low, moderate and high intensity is summed for each category (A minimum of 150 minutes on moderate intensity or 75 minutes on high intensity are equal to health enhancing physical activity according to World Health Organization guidelines) 0-12 months
Secondary Objective assessment of physical activity Accelerometer to assess habitual physical activity during a typical week. Total time of physical activity and physical activity pattern assessed as time spent at different physical activity intensity levels are obtained using the metabolic equivalent of task values (METS). (Higher METs value indicate higher physical activity level.) 0-12 weeks
Secondary Objective assessment of physical activity Accelerometer to assess habitual physical activity during a typical week. Total time of physical activity and physical activity pattern assessed as time spent at different physical activity intensity levels are obtained using the metabolic equivalent of task values (METS). (Higher METs value indicate higher physical activity level.) 0-6 months
Secondary Objective assessment of physical activity Accelerometer to assess habitual physical activity during a typical week. Total time of physical activity and physical activity pattern assessed as time spent at different physical activity intensity levels are obtained using the metabolic equivalent of task values (METS). (Higher METs value indicate higher physical activity level.) 0-12 months
Secondary Pain intensity Visual Analogue Scale (VAS) (0-100, Higher score indicate worse pain) 0-12 weeks
Secondary Pain intensity Visual Analogue Scale (VAS) (0-100, Higher score indicate worse pain) 0-6 months
Secondary Pain intensity Visual Analogue Scale (VAS) (0-100, Higher score indicate worse pain) 0-12 months
Secondary Global health Visual Analogue Scale (VAS) (0-100, Higher score indicate worse health) 0-12 weeks
Secondary Global health Visual Analogue Scale (VAS) (0-100, Higher score indicate worse health) 0-6 months
Secondary Global health Visual Analogue Scale (VAS) (0-100, Higher score indicate worse health) 0-12 months
Secondary Fatigue The Multiple Fatigue Inventory (MFI-20) (4-20 for each subscale, Higher score indicates a higher degree of fatigue 0-12 weeks
Secondary Fatigue The Multiple Fatigue Inventory (MFI-20) (4-20 for each subscale, Higher score indicates a higher degree of fatigue 0-6 months
Secondary Fatigue The Multiple Fatigue Inventory (MFI-20) (4-20 for each subscale, Higher score indicates a higher degree of fatigue 0-12 months
Secondary Sleep Pittsburgh Sleep Quality Index (0-21, Higher score indicate worse sleep quality). 0-12 weeks
Secondary Sleep Pittsburgh Sleep Quality Index (0-21, Higher score indicate worse sleep quality). 0-6 months
Secondary Sleep Pittsburgh Sleep Quality Index (0-21, Higher score indicate worse sleep quality). 0-12 months
Secondary Activity limitations Health Assessment Questionnaire (HAQ) (0-3, Higher score indicate worse activity limitations) 0-12 weeks
Secondary Activity limitations Health Assessment Questionnaire (HAQ) (0-3, Higher score indicate worse activity limitations) 0-6 months
Secondary Activity limitations Health Assessment Questionnaire (HAQ) (0-3, Higher score indicate worse activity limitations) 0-12 months
Secondary Attitude to exercise Exercise Health Beliefs questionnaire (20-100, Higher score represents stronger exercise health beliefs. 0-12 weeks
Secondary Attitude to exercise Exercise Health Beliefs questionnaire (20-100, Higher score represents stronger exercise health beliefs. 0-6 moths
Secondary Attitude to exercise Exercise Health Beliefs questionnaire (20-100, Higher score represents stronger exercise health beliefs. 0-12 months
Secondary Body compositions Weight and height will be combined to report Body mass index BMI kg/m2 (A higher score indicate higher relative weight) 0-12 weeks
Secondary Waist circumference Measured with a tape measure midway between the lower rib and iliac crest. (A waist measurement of 80 centimeters or more for women and 94 centimeters or more for men indicate increased risk for diseases related to overweight) 0-12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4